JP2019534246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534246A5 JP2019534246A5 JP2019512234A JP2019512234A JP2019534246A5 JP 2019534246 A5 JP2019534246 A5 JP 2019534246A5 JP 2019512234 A JP2019512234 A JP 2019512234A JP 2019512234 A JP2019512234 A JP 2019512234A JP 2019534246 A5 JP2019534246 A5 JP 2019534246A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- domain
- vector
- vectors
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 55
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 24
- 230000004068 intracellular signaling Effects 0.000 claims 18
- 210000004698 lymphocyte Anatomy 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 230000001024 immunotherapeutic effect Effects 0.000 claims 12
- 238000009169 immunotherapy Methods 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000000259 anti-tumor effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- -1 c-Met Proteins 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102100032558 Glypican-2 Human genes 0.000 claims 1
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001014664 Homo sapiens Glypican-2 Proteins 0.000 claims 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000012191 childhood neoplasm Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000013601 cosmid vector Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000024558 digestive system cancer Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 101150103001 mEFG1 gene Proteins 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022100960A JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024110705A JP2024150518A (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382791P | 2016-09-02 | 2016-09-02 | |
| US62/382,791 | 2016-09-02 | ||
| PCT/US2017/049923 WO2018045325A1 (en) | 2016-09-02 | 2017-09-01 | Compositions and methods for treating cancer with duocars |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100960A Division JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534246A JP2019534246A (ja) | 2019-11-28 |
| JP2019534246A5 true JP2019534246A5 (OSRAM) | 2020-08-06 |
| JP7160482B2 JP7160482B2 (ja) | 2022-10-25 |
Family
ID=60022150
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512234A Active JP7160482B2 (ja) | 2016-09-02 | 2017-09-01 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2021514984A Active JP7423610B2 (ja) | 2016-09-02 | 2019-09-18 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2022529859A Active JP7766595B2 (ja) | 2016-09-02 | 2020-11-20 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
| JP2022100960A Active JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024005142A Pending JP2024054133A (ja) | 2016-09-02 | 2024-01-17 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2024110705A Pending JP2024150518A (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514984A Active JP7423610B2 (ja) | 2016-09-02 | 2019-09-18 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2022529859A Active JP7766595B2 (ja) | 2016-09-02 | 2020-11-20 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
| JP2022100960A Active JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024005142A Pending JP2024054133A (ja) | 2016-09-02 | 2024-01-17 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2024110705A Pending JP2024150518A (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US11453712B2 (OSRAM) |
| EP (4) | EP3507304B1 (OSRAM) |
| JP (6) | JP7160482B2 (OSRAM) |
| CN (5) | CN117298260A (OSRAM) |
| AU (4) | AU2017321894B2 (OSRAM) |
| CA (3) | CA3035615A1 (OSRAM) |
| ES (1) | ES2981703T3 (OSRAM) |
| WO (3) | WO2018045325A1 (OSRAM) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| US10676528B2 (en) * | 2013-12-06 | 2020-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| HK1258869A1 (zh) | 2015-09-18 | 2019-11-22 | Twist Bioscience Corporation | 寡核酸变体文库及其合成 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| US11453712B2 (en) | 2016-09-02 | 2022-09-27 | Lentigen Technology Inc. | Compositions and methods for treating cancer with DuoCARs |
| US10417457B2 (en) | 2016-09-21 | 2019-09-17 | Twist Bioscience Corporation | Nucleic acid based data storage |
| US11550939B2 (en) | 2017-02-22 | 2023-01-10 | Twist Bioscience Corporation | Nucleic acid based data storage using enzymatic bioencryption |
| CN110997719B (zh) * | 2017-03-24 | 2020-12-11 | 莱蒂恩技术公司 | 用于用抗cd33免疫疗法治疗癌症的组合物和方法 |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| IL271205B2 (en) | 2017-06-12 | 2025-02-01 | Twist Bioscience Corp | Methods for assembling continuous nucleic acids |
| WO2019028051A1 (en) * | 2017-07-31 | 2019-02-07 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY |
| GB2581620A (en) | 2017-09-11 | 2020-08-26 | Twist Bioscience Corp | GPCR binding proteins and synthesis thereof |
| EP4279584A3 (en) * | 2017-10-16 | 2024-03-06 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd22 immunotherapy |
| CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| GB2585506A (en) | 2018-01-04 | 2021-01-13 | Twist Bioscience Corp | DNA-based digital information storage |
| CA3100739A1 (en) | 2018-05-18 | 2019-11-21 | Twist Bioscience Corporation | Polynucleotides, reagents, and methods for nucleic acid hybridization |
| WO2019246261A1 (en) * | 2018-06-19 | 2019-12-26 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| AU2019290230A1 (en) * | 2018-06-22 | 2020-12-03 | The General Hospital Corporation | Chimeric antigen receptors targeting CD37 and CD19 |
| CN112638402A (zh) * | 2018-07-03 | 2021-04-09 | Sotio有限责任公司 | 与增强葡萄糖输入的反式代谢分子组合的嵌合受体及其治疗用途 |
| WO2020033273A1 (en) * | 2018-08-04 | 2020-02-13 | AbCyte Therapeutics Inc. | Multi-function and multi-targeting car system and methods for use thereof |
| US11242389B2 (en) | 2018-09-26 | 2022-02-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy |
| CA3114349A1 (en) * | 2018-09-26 | 2020-04-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
| EP3902816A4 (en) | 2018-12-26 | 2022-09-14 | Twist Bioscience Corporation | HIGHLY ACCURATE POLYNUCLEOTIDE DE NOVO SYNTHESIS |
| CN109485734B (zh) * | 2018-12-30 | 2020-05-12 | 广州百暨基因科技有限公司 | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 |
| EP3908613A4 (en) * | 2019-01-07 | 2022-10-19 | Celluris Participações Ltda. | BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA |
| JP7531502B2 (ja) * | 2019-02-15 | 2024-08-09 | アドヴァンスド セル ダイアグノスティクス，インコーポレイテッド | ｉｎ ｓｉｔｕハイブリダイゼーションによって、核酸をマルチプレックス検出する方法 |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| JP2022521551A (ja) | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| US11969443B2 (en) * | 2019-03-06 | 2024-04-30 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
| WO2020183131A1 (en) * | 2019-03-08 | 2020-09-17 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| US20220160771A1 (en) * | 2019-04-10 | 2022-05-26 | Iulia Diaconu | Flt3-specific chimeric antigen receptors and methods of using the same |
| AU2020265679A1 (en) | 2019-04-30 | 2021-12-23 | Senti Biosciences, Inc. | Chimeric receptors and methods of use thereof |
| EP3965897A4 (en) * | 2019-05-07 | 2023-01-04 | The Board of Trustees of the Leland Stanford Junior University | CHEMERA ANTIGEN RECEPTORS TARGETING GLYPICAN-2 |
| KR20220010722A (ko) * | 2019-05-16 | 2022-01-26 | 난징 레전드 바이오테크 씨오., 엘티디. | Cd4 결합 모이어티를 포함하는 면역 세포 수용체 |
| EP3980453A4 (en) * | 2019-06-07 | 2023-07-05 | The Trustees of the University of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| BR112021025259A2 (pt) * | 2019-06-14 | 2022-03-15 | 2Seventy Bio Inc | Composições e métodos para tratar câncer |
| AU2020298294A1 (en) | 2019-06-21 | 2022-02-17 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| US20220252601A1 (en) * | 2019-07-18 | 2022-08-11 | Jw Bioscience | Antibody specifically binding to wrs protein, and use thereof |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| CN114929751B (zh) * | 2019-09-27 | 2024-11-05 | 南京艾美斐生物医药科技有限公司 | Ror1特异性嵌合抗原受体及其治疗应用 |
| WO2021092593A1 (en) * | 2019-11-08 | 2021-05-14 | The University Of North Carolina At Chapel Hill | Use of agonists to augment car t function in solid tumors |
| CN112812182B (zh) * | 2019-11-15 | 2023-01-06 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4的单链抗体、嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN112813030A (zh) * | 2019-11-15 | 2021-05-18 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4和dr5的嵌合抗原受体t细胞及其制备方法和应用 |
| AR120563A1 (es) * | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quimérico cd19 y cd22 y sus usos |
| US20230084763A1 (en) | 2020-03-02 | 2023-03-16 | Yvonne Yu-Hsuan CHEN | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
| CA3171101A1 (en) * | 2020-06-22 | 2021-12-30 | Dina SCHNEIDER | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
| US20230256064A1 (en) * | 2020-07-23 | 2023-08-17 | Medytox Inc. | Cancer therapeutic agent |
| AU2021331088A1 (en) | 2020-08-26 | 2023-05-04 | Twist Bioscience Corporation | Methods and compositions relating to glp1r variants |
| EP4210832A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| CA3200265A1 (en) * | 2020-10-30 | 2022-05-05 | The University Of North Carolina At Chapel Hill | Dual targeting chimeric antigen receptors |
| CN116801898A (zh) * | 2020-11-05 | 2023-09-22 | 莱蒂恩技术公司 | 用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法 |
| CN114539421B (zh) * | 2020-11-18 | 2024-03-12 | 复旦大学 | 以HIV-1 gp120与CD20为双靶点的CAR-T细胞制备方法及其应用 |
| TW202307210A (zh) * | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| CA3228773A1 (en) * | 2021-08-12 | 2023-02-16 | Gaurav KHARYA | Chimeric antigen receptors (car) for b cell malignancies |
| JP2024536279A (ja) * | 2021-10-01 | 2024-10-04 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 抗体を担持した免疫細胞及び癌治療における使用方法 |
| AR128124A1 (es) | 2021-12-30 | 2024-03-27 | Tr1X Inc | Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estos |
| CN119923410A (zh) * | 2022-07-28 | 2025-05-02 | 莱蒂恩技术公司 | 用于治疗实体瘤的嵌合抗原受体治疗 |
| EP4565265A2 (en) * | 2022-08-04 | 2025-06-11 | Lyell Immunopharma, Inc. | Methods of manufacturing chimeric antigen receptor t cells |
| EP4331546A1 (en) | 2022-08-31 | 2024-03-06 | HyPro Innovation GmbH | Absorbent thermal effect pad |
| WO2024220598A2 (en) * | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2025051339A1 (en) | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| EP4520346A1 (en) | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025081163A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US498298A (en) | 1893-05-30 | Range | ||
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| CA2129514A1 (en) | 1992-03-12 | 1993-09-16 | M. Amin Khan | Controlled released acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| WO2005003345A2 (en) * | 2003-06-27 | 2005-01-13 | R. Crea & Co. | Look-through mutagenesis |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| JP2013505944A (ja) | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20110212088A1 (en) | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| DK3473707T3 (da) | 2012-05-25 | 2025-03-17 | Cellectis | Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| ES2718903T3 (es) | 2012-10-24 | 2019-07-05 | Us Health | Receptores de antígenos quiméricos M971 |
| US9217807B2 (en) | 2013-07-23 | 2015-12-22 | Schlumberger Technology Corporation | Systems and methods for identifying sanding in production wells using time-lapse sonic data |
| DK3071222T3 (da) * | 2013-11-21 | 2020-11-16 | Ucl Business Ltd | Celle |
| US10676528B2 (en) | 2013-12-06 | 2020-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| EP3149044B1 (en) | 2014-06-02 | 2020-10-21 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Chimeric antigen receptors targeting cd-19 |
| SG10201913765YA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| EP3018200A1 (en) * | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| CN114107212A (zh) * | 2014-12-24 | 2022-03-01 | 奥托路斯有限公司 | 细胞 |
| WO2016172537A1 (en) | 2015-04-23 | 2016-10-27 | The Trustees Of The University Of Pennsylvania | Compositions to disrupt protein kinase a anchoring and uses thereof |
| KR20180118249A (ko) | 2015-04-30 | 2018-10-30 | 싸이오서스 테라퓨틱스 엘티디. | B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스 |
| US20190119635A1 (en) * | 2015-05-05 | 2019-04-25 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| CN108603170A (zh) * | 2015-06-12 | 2018-09-28 | 莱蒂恩技术公司 | 用工程改造的t细胞治疗癌症的方法 |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| WO2016210447A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| EP3660044A1 (en) | 2015-10-09 | 2020-06-03 | Miltenyi Biotec Technology, Inc. | Chimeric antigen receptors and methods of use |
| CN105331586B (zh) | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
| CN108712907A (zh) | 2016-03-11 | 2018-10-26 | 哈摩尼克制药公司 | 包含天然提取物的舌下组合物及其用途 |
| US11453712B2 (en) | 2016-09-02 | 2022-09-27 | Lentigen Technology Inc. | Compositions and methods for treating cancer with DuoCARs |
| CN110997719B (zh) | 2017-03-24 | 2020-12-11 | 莱蒂恩技术公司 | 用于用抗cd33免疫疗法治疗癌症的组合物和方法 |
| CN108220247A (zh) * | 2018-03-20 | 2018-06-29 | 杭州史迪姆生物科技有限公司 | 一种双car-t细胞及其制备方法和应用 |
-
2017
- 2017-09-01 US US16/078,269 patent/US11453712B2/en active Active
- 2017-09-01 AU AU2017321894A patent/AU2017321894B2/en active Active
- 2017-09-01 ES ES17780539T patent/ES2981703T3/es active Active
- 2017-09-01 EP EP17780539.7A patent/EP3507304B1/en active Active
- 2017-09-01 CA CA3035615A patent/CA3035615A1/en active Pending
- 2017-09-01 CN CN202311164481.5A patent/CN117298260A/zh active Pending
- 2017-09-01 JP JP2019512234A patent/JP7160482B2/ja active Active
- 2017-09-01 EP EP23184693.2A patent/EP4282969A3/en active Pending
- 2017-09-01 CN CN201780061243.8A patent/CN109843922B/zh active Active
- 2017-09-01 WO PCT/US2017/049923 patent/WO2018045325A1/en not_active Ceased
-
2018
- 2018-09-18 US US16/134,735 patent/US10689431B2/en active Active
-
2019
- 2019-09-18 JP JP2021514984A patent/JP7423610B2/ja active Active
- 2019-09-18 CN CN201980072801.XA patent/CN113382745B/zh active Active
- 2019-09-18 CN CN202410358222.4A patent/CN118370808A/zh active Pending
- 2019-09-18 CA CA3113194A patent/CA3113194A1/en active Pending
- 2019-09-18 EP EP19790096.2A patent/EP3852789A2/en active Pending
- 2019-09-18 WO PCT/US2019/051734 patent/WO2020061194A2/en not_active Ceased
- 2019-09-18 AU AU2019342730A patent/AU2019342730A1/en active Pending
- 2019-11-22 US US16/692,957 patent/US11208455B2/en active Active
-
2020
- 2020-06-22 US US16/907,713 patent/US11802142B2/en active Active
- 2020-11-20 JP JP2022529859A patent/JP7766595B2/ja active Active
- 2020-11-20 AU AU2020386636A patent/AU2020386636A1/en active Pending
- 2020-11-20 EP EP20825051.4A patent/EP4061407A1/en active Pending
- 2020-11-20 WO PCT/US2020/061623 patent/WO2021102337A1/en not_active Ceased
- 2020-11-20 CN CN202080092701.6A patent/CN115768462A/zh active Pending
- 2020-11-20 CA CA3158878A patent/CA3158878A1/en active Pending
-
2021
- 2021-12-02 US US17/540,377 patent/US12365718B2/en active Active
-
2022
- 2022-05-25 US US17/752,966 patent/US20220281946A1/en active Pending
- 2022-06-23 JP JP2022100960A patent/JP7522156B2/ja active Active
-
2023
- 2023-07-06 US US18/347,644 patent/US20240025962A1/en active Pending
- 2023-09-12 US US18/465,233 patent/US20240043497A1/en active Pending
-
2024
- 2024-01-17 JP JP2024005142A patent/JP2024054133A/ja active Pending
- 2024-07-10 JP JP2024110705A patent/JP2024150518A/ja active Pending
-
2025
- 2025-01-24 AU AU2025200478A patent/AU2025200478A1/en active Pending
- 2025-06-17 US US19/240,490 patent/US20250367291A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534246A5 (OSRAM) | ||
| JPWO2021102337A5 (OSRAM) | ||
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| JP7566817B2 (ja) | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 | |
| JP7179041B2 (ja) | 三官能性ｔ細胞－抗原カプラ及び方法並びにこれらの使用 | |
| JP7267321B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| JP7177794B2 (ja) | 抗ｔｒｂｃ１抗原結合ドメイン | |
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| JP7000315B2 (ja) | 高結合活性ｈｐｖ ｔ細胞受容体 | |
| ES2905557T3 (es) | Receptor de antígeno quimérico anti-CD30 y su uso | |
| JP7662588B2 (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| WO2019109980A1 (zh) | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 | |
| CN110520524A (zh) | 靶向肿瘤微环境的嵌合抗原受体t细胞 | |
| JP2020530989A5 (OSRAM) | ||
| KR20190101979A (ko) | 합성 면역 수용체 및 이의 사용 방법 | |
| CA3093705A1 (en) | Anti-gucy2c chimeric antigen receptor compositions and methods | |
| WO2014055657A1 (en) | Use of a trans-signaling approach in chimeric antigen receptors | |
| Chmielewski et al. | T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term | |
| CN112442509A (zh) | Cd19-cd20双特异性和双通道car-t及其使用方法 | |
| WO2017179015A1 (en) | Compositions for the treatment of cancer | |
| JPWO2020181164A5 (OSRAM) | ||
| Heard et al. | Advances in CAR design | |
| CN114438033A (zh) | 靶向pd-1h（vista）的抗肿瘤免疫治疗方法 | |
| CN110540997A (zh) | 靶向bcma嵌合抗原受体、核酸序列、载体及应用 | |
| JP2024535781A (ja) | 抗原結合タンパク質およびその使用 |